E Fund Management Co. Ltd. Acquires Shares of 5,810 Halozyme Therapeutics, Inc. $HALO

E Fund Management Co. Ltd. bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,810 shares of the biopharmaceutical company’s stock, valued at approximately $455,000.

Other large investors have also recently modified their holdings of the company. Norges Bank bought a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $128,201,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics in the fourth quarter valued at about $124,031,000. Voloridge Investment Management LLC bought a new position in Halozyme Therapeutics in the third quarter valued at about $77,587,000. Qube Research & Technologies Ltd acquired a new position in Halozyme Therapeutics during the second quarter worth about $51,295,000. Finally, Assenagon Asset Management S.A. raised its stake in Halozyme Therapeutics by 4,578.9% during the second quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock worth $78,086,000 after acquiring an additional 976,321 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 64,103 shares of company stock worth $5,226,496 in the last ninety days. Company insiders own 2.50% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of research analyst reports. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Morgan Stanley lowered their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $106.12 on Friday. The stock has a 50-day moving average price of $82.42 and a two-hundred day moving average price of $73.50. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $107.96. The company has a market capitalization of $12.04 billion, a PE ratio of 31.68, a P/E/G ratio of 0.43 and a beta of 0.85. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. During the same period in the previous year, the business posted $1.54 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts expect that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.